How India Exports Itraconazole to the World

Itraconazole, an antifungal agent, has been approved by the U.S. Food and Drug Administration (FDA) for various indications. According to the FDA's Orange Book, multiple Abbreviated New Drug Applications (ANDAs) have been approved for itraconazole, indicating a competitive generic market. Notably, on October 30, 2008, the FDA granted orphan drug designation to an itraconazole suspension for the topical treatment of fungal otitis externa (otomycosis); however, this indication has not yet received FDA approval.

The United States is the primary destination for itraconazole exports from India, accounting for 33.5% of the total export value. This substantial market share underscores the importance of compliance with FDA regulations for Indian exporters. The presence of 285 active Indian exporters and a repeat buyer rate of 48.5% reflect a robust and consistent demand in the U.S. market.

In the European Union (EU), itraconazole is subject to the European Medicines Agency's (EMA) marketing authorization process. On August 23, 2017, the EMA granted orphan designation to itraconazole for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome); however, this designation was withdrawn in July 2023 at the sponsor's request. (ema.europa.eu) Additionally, on May 25, 2018, itraconazole received orphan designation for the prevention of invasive aspergillosis. (ema.europa.eu)

The United Kingdom, following its departure from the EU, has established its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). While specific data on itraconazole's status within the UK is not provided, compliance with MHRA regulations is essential for market access.

Itraconazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its significance in treating fungal infections. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, itraconazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for itraconazole, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products; however, itraconazole is not currently listed among those requiring an export NOC.

The primary patents for itraconazole have expired, leading to increased generic competition globally. This competitive landscape is evident in the substantial number of Indian exporters (285) and the diverse range of destination countries (123) for itraconazole exports.

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension to the existing indication for Noxafil (posaconazole), a related antifungal agent, for the treatment of invasive aspergillosis in adults and pediatric patients from 2 years of age weighing more than 40 kg. (ema.europa.eu)

In July 2023, the EMA withdrew the orphan designation for itraconazole for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome) at the sponsor's request. (ema.europa.eu)

In May 2018, the EMA granted orphan designation to itraconazole for the prevention of invasive aspergillosis, recognizing its potential in addressing this serious condition. (ema.europa.eu)

In April 2009, the EMA's CHMP concluded that the benefits of Prokanazol, an itraconazole-containing medicine, did not outweigh its risks, leading to the suspension of its marketing authorization in the Czech Republic. (ema.europa.eu)

In October 2005, the European Commission granted a marketing authorization for Posaconazole SP, an antifungal agent, for the treatment of various fungal infections in adults. However, the marketing authorization lapsed in November 2008 due to the product not being marketed within three years of authorization. (ema.europa.eu)

These developments underscore the dynamic nature of the antifungal pharmaceutical market and the importance of staying abreast of regulatory changes and market trends.

India is a leading producer of Active Pharmaceutical Ingredients (APIs), including Itraconazole. However, the Indian pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates essential for API synthesis. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have exacerbated these vulnerabilities. In February 2026, escalating conflicts in the Middle East, particularly the closure of the Strait of Hormuz, disrupted global shipping routes and energy supplies. This crisis led to increased transportation costs and delays, impacting the timely procurement of raw materials from China to India. Such disruptions underscore the fragility of the supply chain for Itraconazole and similar pharmaceuticals.

Our proprietary trade data indicates that the top five Indian exporters of Itraconazole account for 54.9% of total exports, with COHANCE LIFESCIENCES LIMITED leading at a 13.4% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce reliance on imports. While this initiative is a positive step, its full impact on diversifying the supplier base and enhancing supply chain resilience for Itraconazole remains to be seen.

The closure of the Strait of Hormuz in February 2026, due to heightened tensions involving Iran, the United States, and Israel, has significantly disrupted global shipping routes. This strait is a critical chokepoint for international trade, and its blockade has led to increased shipping costs and delays. Additionally, the Red Sea has experienced disruptions from Houthi forces, further complicating maritime logistics. These geopolitical events have strained supply chains, including those for pharmaceuticals like Itraconazole.

Furthermore, ongoing U.S.-China tensions have introduced additional uncertainties. Trade restrictions and tariffs have the potential to disrupt the flow of raw materials and finished pharmaceutical products. While specific shortage alerts from regulatory bodies like the FDA or EMA have not been issued for Itraconazole as of March 2026, the cumulative effect of these geopolitical factors poses a tangible risk to its supply chain.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to strengthen local manufacturing capabilities for critical raw materials and APIs.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to circumvent disrupted areas, ensuring continuity in supply chains.

• Implement Robust Risk Monitoring: Utilize advanced analytics to monitor geopolitical developments and assess their potential impact on supply chains proactively.

• Strengthen Inventory Management: Maintain strategic stockpiles of essential raw materials and finished products to buffer against supply disruptions.

RISK_LEVEL: MEDIUM